 |
|
| Type | Public (NYSE: AGN) |
|---|---|
| Founded | 1948 |
| Headquarters | Irvine, California |
| Key people | David E.I. Pyott, Chairman of the Board, CEO, F. Michael Ball, President |
| Industry | Pharmaceuticals |
| Products | Botox, Acular, Alocril, Prevage, Avage, Tazorac, Juvederm, Lap-band, Easyband,Restasis, Alphagan, Ganfort, Hydrafill, Optive |
| Revenue | $3.9 billion USD FY 2007 |
| Employees | 8,500 |
| Website | www.allergan.com |
Allergan, Inc., is a global specialty pharmaceutical company. Their product ranges include ophthalmic pharmaceuticals, dermatology products, and neurological products.
Contents |
Profile
The company's most notable neurologic product is Botox, used around the world to treat a variety of debilitating disorders associated with muscle overactivity and also well-known—under the trade names Botox Cosmetic and Vistabel—for the treatment of facial lines.
Its most important manufacturing plants are in Waco, Texas; Westport, Ireland; and San Jose, Costa Rica.
History
1950: Allergan launched its first product, NASAL DROPS
1962: Allergan achieves $1 million in eye care sales
1966: Worldwide corporate headquarters was established in Irvine by acquiring a 28-acre (110,000 m2) parcel of land
1970: Allergan becomes publicly traded and achieves $10 million in sales
1978: Started manufacturing in Ireland
1980: Subsidiaries are in 30 countries and products are marketed in more than 100 countries sales reach $100 million
1980: Allergan was acquired by SmithKline Beecham plc (then known as "SmithKline Corporation" and herein "SmithKline"). Allergan operated as a wholly-owned subsidiary of SmithKline from 1980 until 1989
1989: Allergan again became a stand-alone public company through a spin-off distribution by SmithKline.
1992: Allergan sold its contact lens business in North and South America.
1993: Allergan sold its contact lens business outside of the Americas.
1994: Allergan acquired the Ioptex Research worldwide intraocular lens product line.
1987 Allergan achieves $500 million in sales
1995 Allergan achieves $1 billion in sales
1995: Allergan completed four acquisitions. In January 1995, Allergan acquired Optical Micro Systems, Inc., a U.S.-based developer and manufacturer of phacoemulsification surgical equipment. In June 1995, Allergan acquired Laboratorios Frumtost, S.A., a manufacturer of ophthalmic and other pharmaceutical products in Brazil. In August 1995, Allergan purchased the assets of Herald Pharmacal, Inc., a U.S.-based developer and manufacturer of glycolic acid-based, aesthetic skin care products. In November 1995, Allergan purchased the worldwide contact lens care product business of Pilkington Barnes Hind. Also in 1995, Allergan acquired 100% ownership interest in Santen-Allergan, its Japanese contact lens care joint venture.
1999: Allergan implemented a two-for-one stock split effected as a dividend to stockholders of record on November 18, 1999.
2002: Botox is born
2004: Allergan achieves $2 billion in sales
2006: Allergan Achieves $3 billion in sales; Lap Band is born
March 2006: Allergan acquired aesthetic company, Inamed, to create a world leading aesthetic brand focused on facial aesthetics, breast aesthetics, and devices designed to treat obesity(lapband).
2007: Breast implants developed (see "Inamed acquisition" below)
February 2007: Allergan acquired the Swiss company Endoart SA based on the EPFL campus. It has special expertise in the field of telemetrically-controlled implants.
Allergan is reported to be investigating the cosmetic properties of Lumigan in clinical trials as of November 2007.[1]
2009: Allergan released above mentioned product under the name "Latisse", an attenuated version of Lumigan (same active ingredient, bimatoprost, in lower concentration).
Products
- NATRELLE: Breast Implants (Silicone and Saline)
- LAP-BAND: An adjustable gastric band, inserted laparoscopically (in most circumstances); a restrictive device implanted via bariatric surgery and designed for obese patients with a body mass index (BMI) of 40 or greater.
- ORBERA SYSTEM: An intragastric balloon, inserted endoscopically; designed to assist weight loss by partially filling the stomach and inducing satiety for overweight patients with a body mass index (BMI) of 27 or greater.
- LUMIGAN: anti-glaucoma medication containing the active ingredient bimatoprost.
- Alphagan P: anti-(glaucoma) medication containing the active ingredient (brimonidine)
- ACULAR
- ZYMAR
- F M L (fluorometholone)
- Combigan: anti-(glaucoma) medication containing a combination of active ingredients (brimonidine) and (timolol)
- BOTOX: anti-spasm medication containing the active ingredient botulinum toxin.
- REFRESH: artificial tears containing carboxymethylcellulose
- CELLUVISC
- DRY EYE THERAPY
- Sensitive
- LACRI-LUBE
- LIQUIGEL
- PLUS
- P.M.
- REDNESS RELIEF
- TEARS
- OPTIVE: most advanced retail dry-eye treatment
- RESTASIS: dry eye treatment containing cyclosporine.
- JUVEDERM: used cosmetically for wrinkles and fine lines, also for lip augmentation
- TAZORAC: for severe acne and psoriasis
- LATISSE: used to lengthen and thicken eyelashes (attenuated version of Lumigan)
- OZURDEX: for BRVO and CRVO
-
This list is incomplete; you can help by expanding it.
Notes
- ^ Wall Street Journal: Drug That Lengthens Eyelashes Sets Off Flutter RHONDA L. RUNDLE November 19, 2007; Page B1
External links
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
